Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Oct 28 2020

Full Issue

Biden May Borrow Germany's Approach To Drug Pricing; Despite Trump's Claims, Drug Prices Are Climbing

Read about the biggest pharmaceutical developments and pricing stories from the past week in KHN's Prescription Drug Watch roundup.

FiercePharma: Biden Looks To Germany For Answers On How To Tackle High U.S. Drug Prices: Analyst 

Democratic presidential nominee Joe Biden is offering clues about how his administration would approach drug pricing—and he's looking to Germany. Under Biden’s plan, the government would set up a group to assess “fair” values of drugs, like the Institute for Clinical and Economic Review already does in the U.S. Other governments have their own drug value assessment agencies, but ICER is not a U.S. government group. Biden made the proposal Sunday night, Bernstein analyst Ronny Gal wrote in a note to clients. (Sagonowsky, 10/20)

Capital and Main: Trump Touts His War On Drug Prices As Costs Continue To Climb

As the days to Nov. 3 dwindle down, the president of the United States has been hand selecting his points of emphasis for rallies and Twitter posts. Often, those choices go against the wishes of his own advisers. Veering away from core issues, Donald Trump has repeatedly invoked Hunter Biden’s name, doubled down on unsupported allegations of mail-in ballot vote fraud, suggested he’ll leave the country if he loses the election and repeated debunked claims that masks are not effective in preventing COVID-19.At most stops, however, Trump has at least attempted to broach one topic that pollsters have repeatedly found to be resonant with voters: the high cost of prescription drugs. And time and again, Trump has not only promised to cut them – “Drug prices will be coming down 80 or 90 percent,” he said during the first presidential debate – but insisted that, functionally, he has already done so. (Kreidler, 10/27)

Forbes: What Biden And Trump Would Mean For Older Voters

As with so many issues, there is a major gulf between President Trump and former Vice President Joe Biden when it comes to issues that directly affect older adults. Biden has proposed a long list of specific proposals. Trump has said remarkably little about what he’d do in a second term, and that silence extends to programs that affect seniors. But over the past four years he has described several initiatives that he could address starting next year. Here is a quick rundown of where each candidate stands on Medicare, Social Security, long-term care, and health insurance for older working adults. (Gleckman, 10/26)

Also —

Stat: Can A Laser Focus On Insulin Prices Take This Advocate To Congress?

Quinn Nystrom’s first campaign ad slammed her opponent for voting against legislation to lower prescription drug costs. So did her second ad. And her third. Nystrom, a 34-year-old with type 1 diabetes, is waging a spite campaign of sorts against her congressman, Pete Stauber. She launched her bid to unseat the freshman Republican after he backed away from a promise to hold a town hall on insulin affordability in their district, Minnesota’s 8th, a 27,000-square-mile expanse that runs from the Ontario border to the outer suburbs of the Twin Cities. (Florko, 10/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF